PT966285E - Utilizacao de (+)mefloquina para o tratamento da malaria - Google Patents

Utilizacao de (+)mefloquina para o tratamento da malaria

Info

Publication number
PT966285E
PT966285E PT98910836T PT98910836T PT966285E PT 966285 E PT966285 E PT 966285E PT 98910836 T PT98910836 T PT 98910836T PT 98910836 T PT98910836 T PT 98910836T PT 966285 E PT966285 E PT 966285E
Authority
PT
Portugal
Prior art keywords
quinolinemethanol
piperidinyl
trifluoromethyl
alpha
bis
Prior art date
Application number
PT98910836T
Other languages
English (en)
Inventor
Allan Fletcher
Robin Shepherd
Original Assignee
Vernalis Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9704809.4A external-priority patent/GB9704809D0/en
Priority claimed from GBGB9722232.7A external-priority patent/GB9722232D0/en
Priority claimed from GBGB9724263.0A external-priority patent/GB9724263D0/en
Priority claimed from GBGB9724712.6A external-priority patent/GB9724712D0/en
Application filed by Vernalis Res Ltd filed Critical Vernalis Res Ltd
Publication of PT966285E publication Critical patent/PT966285E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
PT98910836T 1997-03-07 1998-03-06 Utilizacao de (+)mefloquina para o tratamento da malaria PT966285E (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9704809.4A GB9704809D0 (en) 1997-03-07 1997-03-07 Chemical compounds
GBGB9722232.7A GB9722232D0 (en) 1997-10-21 1997-10-21 Chemical compounds
GBGB9724263.0A GB9724263D0 (en) 1997-11-17 1997-11-17 Chemical compounds
GBGB9724712.6A GB9724712D0 (en) 1997-11-21 1997-11-21 Chemical compounds

Publications (1)

Publication Number Publication Date
PT966285E true PT966285E (pt) 2002-12-31

Family

ID=27451612

Family Applications (1)

Application Number Title Priority Date Filing Date
PT98910836T PT966285E (pt) 1997-03-07 1998-03-06 Utilizacao de (+)mefloquina para o tratamento da malaria

Country Status (11)

Country Link
US (1) US6664397B1 (pt)
EP (1) EP0966285B1 (pt)
JP (1) JP4380800B2 (pt)
AT (1) ATE225177T1 (pt)
AU (1) AU730818B2 (pt)
DE (1) DE69808440T2 (pt)
DK (1) DK0966285T3 (pt)
ES (1) ES2185153T3 (pt)
HK (1) HK1024631A1 (pt)
PT (1) PT966285E (pt)
WO (1) WO1998039003A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1251499A (en) * 1997-11-26 1999-06-15 Cerebrus Limited (-)-mefloquine to block purinergic receptors and to treat movement or neurodegenerative disorders
GB0021776D0 (en) 2000-09-05 2000-10-18 Arakis Ltd The treatment of inflammatory disorders
GB0406014D0 (en) * 2004-03-17 2004-04-21 Arakis Ltd Pharmaceutical composition and use
WO2006138487A2 (en) * 2005-06-14 2006-12-28 The Johns Hopkins University Treatment of ischemia-induced arrhythmias
JP2009527478A (ja) * 2006-02-16 2009-07-30 ザ マクレーン ホスピタル コーポレーション パーキンソン病の治療のための方法と組成物
US20110039888A1 (en) * 2008-04-21 2011-02-17 Coltart Don M Asymmetric alpha functionalization and alpha, alpha bisfunctionalization of aldehydes and ketones
US8293783B2 (en) * 2009-03-24 2012-10-23 National University Of Singapore Use of artemisinin derivatives for the treatment of asthma and chronic obstructive pulmonary disease (COPD)
WO2012068560A2 (en) 2010-11-18 2012-05-24 Jenrin Discovery 4-quinolinemethanols as anti-malarial agents
EP2487157A1 (en) 2011-02-11 2012-08-15 Université de Picardie Jules Verne Enantioselective synthesis method of 4-aminoalcoholquinoline derivatives and the use
CN104619323B (zh) 2012-08-09 2018-03-09 坎-菲特生物药物有限公司 用于在治疗性功能障碍中使用的a3腺苷受体配体
CN103304538B (zh) * 2013-06-21 2014-12-24 中国人民解放军第四军医大学 右旋甲氟喹的合成
CN107149601B (zh) * 2017-05-25 2020-04-17 中国中医科学院中药研究所 青蒿素类化合物在制备治疗神经病理性疼痛和/或并发症的药物中的应用
JP7242691B2 (ja) 2017-11-03 2023-03-20 ウニヴェルシト・アミアン・ピカルディ・ジュール・ヴェルヌ 新規なアミノピリジンメタノール化合物及びその使用
CN110507646A (zh) * 2019-09-12 2019-11-29 广州中医药大学(广州中医药研究院) 青蒿素衍生物在制备抗焦虑症的药物或缓解焦虑症的食品中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3630200A (en) 1969-06-09 1971-12-28 Alza Corp Ocular insert
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
DE2940443A1 (de) 1979-10-05 1981-04-16 Basf Ag, 6700 Ludwigshafen Verfahren zur herstellung von erythro-(alpha)-2-piperidyl-2,8-bis-(trifluormethyl)-4-chinolin-methanol
GB8322007D0 (en) 1983-08-16 1983-09-21 Wellcome Found Pharmaceutical delivery system
US4769027A (en) 1984-08-15 1988-09-06 Burroughs Wellcome Co. Delivery system

Also Published As

Publication number Publication date
DE69808440T2 (de) 2003-07-10
JP4380800B2 (ja) 2009-12-09
DK0966285T3 (da) 2002-10-28
US6664397B1 (en) 2003-12-16
DE69808440D1 (de) 2002-11-07
AU6506898A (en) 1998-09-22
ATE225177T1 (de) 2002-10-15
ES2185153T3 (es) 2003-04-16
WO1998039003A1 (en) 1998-09-11
AU730818B2 (en) 2001-03-15
EP0966285A1 (en) 1999-12-29
HK1024631A1 (en) 2000-10-20
EP0966285B1 (en) 2002-10-02
JP2001526637A (ja) 2001-12-18

Similar Documents

Publication Publication Date Title
CA2375908A1 (en) Highly selective norepinephrine reuptake inhibitors and methods of using the same
TR200000129T2 (tr) Yepyeni spiroazabisiklik heterosiklik bileşikler.
RU2011138835A (ru) Применение производного рапамицина
PT966285E (pt) Utilizacao de (+)mefloquina para o tratamento da malaria
DK0959888T3 (da) Anvendelse af det chelerende middel clioquinol til fremstillingen af et farmaceutisk præparat til behandlingen af Alzheimer's sygdom
GEP20043354B (en) Therapeutic Formulation for Administering Tolterodine with Controlled Release
DK0998287T3 (da) Anvendelse af levobupivacain
CA2283255A1 (en) Use of r-nsaid's for the prevention of alzheimer's disease
RS52011B (sr) Nova primena derivata taksoida
EE200300129A (et) Distamütsiini alfa-halogenoakrüloüülderivaadi kasutamine
EP0799618A3 (en) Use of alpha1-adrenoreceptor antagonists in the manufacture of a medicament for the prevention and teatment of cancer
EP1632235A3 (en) Use of highly selective norepinephrine reuptake inhibitors for the treatment of mental disorders
ATE334982T1 (de) 7-chlor-4-hydroxy-2-(2-pyridylethyl)-1,2,5,10-
CA2387394A1 (en) Use of 1-aminoindan derivatives for treatment of mania in bipolar mood disorder
TH42959A (th) สารประกอบเคมี
AU4918900A (en) Interferon-beta use in the treatment of ewing's family of tumors
CA2543986A1 (en) Norepinephrine reuptake inhibitors and methods of using the same
GEP20094628B (en) (s,s)-reboxetine for treating fibromyalgia and other somatoform disorders